An Expert Report on the Ophthalmic Non-Steroidal Anti-Inflammatory Drug: Nepafenac

Executive Summary

Nepafenac (DrugBank ID: DB06802) is a topical non-steroidal anti-inflammatory drug (NSAID) distinguished by its unique prodrug structure and its critical role in contemporary ophthalmic care. Primarily indicated for the prevention and treatment of pain and inflammation associated with cataract surgery, Nepafenac represents a sophisticated approach to ocular drug delivery. This report provides a comprehensive analysis of its chemical properties, pharmacological mechanisms, clinical performance, safety profile, and regulatory history.

The core of Nepafenac's therapeutic value lies in its design as a prodrug. Following topical administration, the lipophilic Nepafenac molecule rapidly penetrates the cornea and is bioactivated by intraocular hydrolases into its active metabolite, amfenac. This conversion occurs preferentially within the target tissues of the anterior and posterior segments, including the iris, ciliary body, and retina. Amfenac is a potent, non-selective inhibitor of both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby blocking the synthesis of prostaglandins, which are key mediators of ocular inflammation and pain. This mechanism of targeted bio-localization not only concentrates the therapeutic effect where it is needed most but also significantly enhances its safety profile, particularly regarding the ocular surface, when compared to NSAIDs administered in their active form.

Pharmacokinetically, Nepafenac is characterized by high, localized concentrations within the eye and minimal systemic exposure. This dichotomy is fundamental to its clinical utility, enabling potent local anti-inflammatory action while mitigating the risks of systemic NSAID-class adverse events. Studies have confirmed its distribution to the posterior segment, providing the scientific rationale for its European indication in reducing the risk of macular edema in diabetic patients undergoing cataract surgery.

Nepafenac is marketed in two principal formulations developed by Alcon (now part of Novartis): Nevanac®, a 0.1% suspension dosed three times daily (TID), and Ilevro®, a 0.3% suspension formulated for more convenient once-daily (QD) dosing. The development of Ilevro® exemplifies a strategic product lifecycle management approach, enhancing patient adherence without compromising efficacy. Clinical trials have robustly demonstrated the superiority of Nepafenac over vehicle in resolving pain and inflammation. Comparative analyses indicate that while its anti-inflammatory efficacy is comparable to other potent ophthalmic NSAIDs like ketorolac, its ocular surface tolerability is superior, a direct consequence of its prodrug nature.

The safety profile is dominated by local ocular effects, such as temporary stinging, and carries warnings common to the ophthalmic NSAID class, including the potential for delayed wound healing and, with prolonged use, serious corneal adverse events. Its regulatory journey, beginning with the FDA approval of Nevanac® in 2005, and its strong intellectual property portfolio have solidified its position as a leading therapeutic option in the management of postoperative ocular inflammation. Future advancements are likely to focus on preservative-free formulations and novel sustained-release delivery systems to further optimize its safety and convenience.

Molecular Profile, Physicochemical Properties, and Formulation

A comprehensive understanding of Nepafenac begins with its molecular identity, its inherent physical and chemical characteristics, and the sophisticated formulation science required to deliver it effectively as a topical ophthalmic agent. The drug's development pathway is a clear illustration of how fundamental physicochemical properties dictate pharmaceutical formulation strategies to overcome challenges like poor solubility and achieve targeted delivery.

Chemical Identification and Structure

Nepafenac is a well-characterized small molecule with a unique chemical identity that is foundational to its pharmacological activity.

Primary Identifiers

The compound is universally identified by a set of standardized codes across major chemical and drug databases:

• Non-proprietary Name: Nepafenac [1]
• DrugBank Identification (ID): DB06802 [1]
• Chemical Abstracts Service (CAS) Number: 78281-72-8 [1]

Nomenclature and Synonyms

To ensure unambiguous identification, a comprehensive list of its chemical names and synonyms is essential.

• International Union of Pure and Applied Chemistry (IUPAC) Name: 2-(2-amino-3-benzoylphenyl)acetamide.[1]
• Common Synonyms and Developmental Codes: The drug is known by numerous synonyms, including its commercial brand names Nevanac and Ilevro, as well as developmental codes such as AHR-9434 and AL 6515. International nonproprietary names include Népafénac (French), Nepafenaco (Spanish), and Nepafenacum (Latin).[1] It is also referred to as "amfenac amide," which describes its chemical relationship to its active metabolite.[1]

Structural Representation

The molecular structure is defined by the following machine-readable formats:

• Simplified Molecular-Input Line-Entry System (SMILES): C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)N [1]
• International Chemical Identifier (InChI): InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18) [1]
• InChI Key: QEFAQIPZVLVERP-UHFFFAOYSA-N [1]

Chemical Classification

From a chemical standpoint, Nepafenac is classified as a monocarboxylic acid amide. It is structurally derived from amfenac, where the carboxylic acid functional group has been converted into a carboxamide.1 This modification is the defining feature of its prodrug status. It also belongs to the broader class of phenylacetic acid derivatives.9

Physicochemical Characteristics

The physical and chemical properties of the Nepafenac molecule are the primary determinants of its behavior in a pharmaceutical formulation and in biological systems.

• Molecular Formula and Weight: The chemical formula is C15​H14​N2​O2​, with a calculated molecular weight of approximately 254.29 g/mol.[2]
• Physical State: In its pure form, Nepafenac is a light yellow to yellow or orange crystalline powder.[4]
• Solubility and Lipophilicity: Nepafenac is practically insoluble in water, a critical property that necessitates its formulation as a suspension rather than a solution.[12] Its lipophilicity is significant, as evidenced by its n-octanol/water partition coefficient ( P) of 128 and a calculated logarithmic partition coefficient (XLogP) of 1.89.[12] This high lipophilicity is a key enabler of its ability to penetrate the lipid-rich layers of the cornea.
• Melting Point: The substance has a melting point in the range of 182 °C to 186 °C.[11]
• Stereochemistry and Polymorphism: Nepafenac is an achiral molecule, meaning it has no stereoisomers and is not optically active.[12] Extensive studies conducted during its development demonstrated no evidence of polymorphism. This crystalline stability is maintained even after the substance undergoes gamma irradiation for sterilization purposes, a crucial factor for ensuring consistent product quality and performance.[12]
• Stability and Storage: The pure drug substance is stable, with data supporting shelf life for up to 52 months under long-term storage conditions (25 °C/60% relative humidity).[12] As a raw material, it is noted as being heat-sensitive and is recommended to be stored under refrigerated conditions (0-10°C).[11] In contrast, the final formulated ophthalmic suspensions are stored at room temperature, protected from light.[15]

Pharmaceutical Development and Ophthalmic Formulations (Nevanac® & Ilevro®)

The pharmaceutical development of Nepafenac is a case study in formulation science, where the inherent properties of the active pharmaceutical ingredient (API) directly guided the creation of a stable, effective, and safe drug product.

Formulation Strategy and Excipient Profile

The primary challenge in formulating Nepafenac was its poor aqueous solubility. This led to the development of a sterile, preserved, multi-dose aqueous suspension for topical ophthalmic administration.12 The objective was to create an isotonic formulation with a physiological pH (approximately 6.75) that could be safely and comfortably administered to the eye.12 The selection of excipients was critical to achieving this goal:

• Suspending Agent: A viscosity-modifying agent, Carbomer (e.g., Carbomer 974P), is used to facilitate the uniform suspension of Nepafenac particles and minimize sedimentation. This ensures that a consistent dose is delivered with each drop.[12]
• Preservative System: Benzalkonium chloride, a broad-spectrum antimicrobial preservative, is included to maintain the sterility of the multi-dose product after opening. Disodium edetate (EDTA) is also added as a preservative aid and a chelating agent.[10]
• Tonicity and Wetting Agents: Mannitol and sodium chloride are used as tonicity agents to make the suspension isotonic with tears, enhancing comfort upon instillation. Tyloxapol is incorporated as a wetting agent to improve the interaction between the drug particles and the aqueous vehicle.[12]

Manufacturing and Quality Control

The manufacturing process is designed to ensure the sterility and physical stability of the suspension. Because the final product packaging (Alcon's proprietary DROP-TAINER® bottle) is heat-liable, terminal sterilization is not feasible. Instead, the process relies on aseptic manufacturing techniques, where the Nepafenac drug substance is first sterilized by gamma irradiation before being added to the sterile vehicle.12

Product performance is not assessed by traditional in-vitro drug release testing, which is more suitable for other dosage forms. Instead, quality and performance are ensured by stringent specifications for several critical physical attributes [13]:

• Particle Size: Controlled to ensure uniformity and prevent irritation.
• Suspension Redispersibility: The product is designed to be easily resuspended with minimal shaking (e.g., within five seconds), guaranteeing dose homogeneity.[12]
• Viscosity: Controlled to optimize suspension stability and ocular residence time.

Commercial Formulations

Two primary formulations have been marketed, representing a clear product lifecycle strategy:

• Nevanac®: The original formulation, containing 0.1% w/v Nepafenac. It is approved for a three-times-daily (TID) dosing regimen.[2]
• Ilevro®: A more recent formulation containing a higher concentration of 0.3% w/v Nepafenac. This product was specifically developed to provide comparable efficacy with a more convenient once-daily (QD) dosing regimen. The Ilevro® formulation also introduced guar gum as an additional excipient, likely to further modify viscosity and drug release characteristics.[2]

The entire development of Nepafenac's ophthalmic formulations is a direct and logical consequence of its molecular properties. The challenge posed by its aqueous insolubility was met with the selection of a suspension dosage form. This, in turn, created the need for a sophisticated system of excipients to ensure physical stability, sterility, and patient comfort. The high lipophilicity, while a challenge for formulation, was the very property leveraged to ensure efficient corneal penetration, linking the drug's chemical nature directly to its biological function.

Pharmacodynamics and Mechanism of Action

The pharmacodynamic profile of Nepafenac is defined by its innovative prodrug approach, which enables targeted delivery and localized bioactivation within the eye. This mechanism is central to its efficacy as an anti-inflammatory agent and contributes significantly to its favorable safety profile.

The Prodrug Advantage: Bioactivation to Amfenac

Nepafenac, in its administered form, is a pharmacologically inactive prodrug.[1] Its therapeutic activity is entirely contingent upon its metabolic conversion to the active molecule, amfenac.[2] This bioactivation is a critical step in its mechanism of action.

Following topical instillation, the lipophilic Nepafenac molecule efficiently permeates the cornea. Once inside the eye, it is rapidly hydrolyzed by intraocular hydrolase enzymes, which are present in various ocular tissues, including the cornea, iris, ciliary body, retina, and choroid.[2] The rate of this enzymatic conversion is not uniform across all tissues; it is highest in the metabolically active retina and choroid, followed by the iris and ciliary body, and is lowest in the cornea.[12] This differential rate of bioactivation ensures that the highest concentrations of the active drug, amfenac, are generated in the very tissues that are the primary sites of postoperative inflammation.

This prodrug strategy confers two major advantages. First, it facilitates the transport of the drug across the corneal barrier by using the inert, more lipophilic Nepafenac molecule as a "transport vessel." Second, by delaying activation until the drug has reached its target intraocular tissues, it minimizes the exposure of the sensitive ocular surface (corneal and conjunctival epithelium) to the potent, active NSAID. This targeted bio-localization is the key pharmacodynamic principle that differentiates Nepafenac from other topical NSAIDs administered in their active form.

Inhibition of Cyclooxygenase (COX-1 and COX-2) Pathways

The active metabolite, amfenac, is a potent non-steroidal anti-inflammatory drug.[22] Its mechanism of action is the inhibition of the enzyme prostaglandin H synthase, which exists in two primary isoforms: cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2).[9]

According to comprehensive database information and regulatory documents, amfenac acts as a non-selective inhibitor, potently and uniformly blocking the activity of both COX-1 and COX-2.[1] While some literature suggests a primary action on COX-2, the consensus view supports dual inhibition.[21] COX-1 is constitutively expressed in many tissues and is involved in homeostatic functions, such as gastric protection and platelet aggregation. COX-2 is typically inducible and is upregulated at sites of inflammation, playing a major role in mediating the inflammatory response. By inhibiting both isoforms, amfenac provides broad and effective anti-inflammatory activity.

Impact on Prostaglandin Synthesis and Ocular Inflammation

The COX enzymes are essential catalysts in the arachidonic acid cascade, responsible for converting arachidonic acid into prostaglandins (PGs) like prostaglandin E2 (PGE2​).[4] Prostaglandins are powerful lipid mediators that play a central role in the inflammatory process. In the eye, they cause vasodilation (leading to redness), increase vascular permeability (leading to edema and protein leakage into the aqueous humor, known as "flare"), and sensitize nerve endings to pain.[9]

By inhibiting the COX enzymes, amfenac effectively blocks the synthesis of these pro-inflammatory prostaglandins. This action has several key therapeutic consequences in the postoperative setting:

• Anti-inflammatory Effect: Reduced prostaglandin levels lead to decreased vasodilation and vascular permeability, which manifests as a reduction in anterior chamber cells and flare.
• Analgesic Effect: By preventing the sensitization of ocular pain receptors, amfenac provides effective pain relief.
• Barrier Stabilization: Surgical trauma to the eye leads to a breakdown of the blood-aqueous barrier. Prostaglandins are a major contributor to this process. By inhibiting their production, Nepafenac helps to maintain the integrity of this barrier.

Preclinical studies in rabbit models of ocular inflammation have confirmed this mechanism. Nepafenac was shown to inhibit prostaglandin synthase with a half-maximal inhibitory concentration (IC50​) of 64.3 µM and to significantly reduce the accumulation of PGE2​ in ocular tissues following an inflammatory stimulus.[6] A single topical dose of Nepafenac can suppress trauma-induced

PGE2​ accumulation for more than six hours in the iris and ciliary body, demonstrating a durable pharmacodynamic effect from a single application.[12] This sustained inhibition provides the rationale for preoperative dosing, ensuring that therapeutic drug levels are present in the tissue at the time of the surgical insult to preemptively blunt the inflammatory cascade.

Comprehensive Pharmacokinetic Profile (ADME)

The pharmacokinetic profile of Nepafenac is a study in contrasts, defined by high, therapeutically effective concentrations within the target ocular tissues and exceedingly low, clinically insignificant concentrations in the systemic circulation. This dual-compartment behavior is the cornerstone of its efficacy and safety, allowing for potent local action with minimal risk of systemic side effects.

Ocular Absorption and Distribution

The journey of Nepafenac from a drop on the ocular surface to its site of action within the eye is a highly efficient process governed by its physicochemical properties.

Corneal Penetration

As a lipophilic molecule, Nepafenac is well-suited to traverse the lipid-rich corneal epithelium, which is often the rate-limiting barrier for ocular drug absorption.21 In vitro studies have demonstrated that Nepafenac penetrates the cornea approximately six times faster than diclofenac, another commonly used ophthalmic NSAID.22 This rapid penetration is the critical first step that allows the prodrug to reach the intraocular tissues where it is converted to its active form.

Distribution to the Posterior Segment

A key pharmacokinetic feature of Nepafenac is its ability to distribute effectively to the posterior segment of the eye, including the choroid and retina, following topical administration.26 This is particularly relevant for its indication in the European Union for reducing the risk of postoperative macular edema in diabetic patients, a condition that affects the retina. Animal studies in both rabbits and monkeys have confirmed the presence of both Nepafenac and its active metabolite, amfenac, in the retina and choroid at pharmacologically relevant concentrations after topical dosing.26

Distribution Pathway and Tissue Reservoir

The pathway for posterior segment delivery is believed to be primarily via a non-corneal route. Rather than diffusing from the anterior chamber through the vitreous, evidence suggests a trans-scleral, choroidal/suprachoroidal, or periocular pathway.26 This results in an observed anterior-to-posterior concentration gradient, with drug levels being highest in the anterior structures and decreasing towards the back of the eye.26 Furthermore, the sustained high concentrations of the prodrug Nepafenac found in posterior tissues suggest that these tissues may act as a drug reservoir. This reservoir can provide a continuous source of Nepafenac for gradual hydrolysis into the active amfenac, potentially contributing to a prolonged duration of action and supporting less frequent dosing regimens.26

Systemic Absorption and Distribution

In stark contrast to its efficient ocular distribution, the systemic absorption of Nepafenac following topical administration is very low.[10]

Plasma Concentrations

Clinical pharmacokinetic studies in human subjects have consistently measured low but quantifiable plasma concentrations of both Nepafenac and amfenac.

• Following three-times-daily (TID) dosing of the 0.1% Nevanac® suspension, the mean steady-state peak plasma concentration (Cmax​) was 0.310 ng/mL for Nepafenac and 0.422 ng/mL for amfenac.[9]
• Following once-daily (QD) dosing of the higher strength 0.3% Ilevro® suspension, the mean steady-state Cmax​ was 0.847 ng/mL for Nepafenac and 1.13 ng/mL for amfenac.[13]

Although the 0.3% formulation results in higher plasma levels, these concentrations are still very low and are not associated with systemic accumulation upon repeated dosing.13 This minimal systemic exposure is the primary reason why dose adjustments are not considered necessary for patients with hepatic or renal impairment.10

Protein Binding

Once in the systemic circulation, the active metabolite, amfenac, exhibits a high affinity for plasma proteins. In vitro studies have shown that it is 95.4% bound to human albumin and 99.1% bound to total human serum proteins.9 This high degree of protein binding further limits the concentration of free, pharmacologically active drug in the systemic circulation, contributing to its systemic safety profile.

Bioactivation and Metabolic Pathways

The metabolism of Nepafenac is a two-stage process, beginning with its essential bioactivation in the eye and followed by extensive systemic metabolism for elimination.

Primary Metabolism (Bioactivation)

As detailed previously, the crucial first metabolic step is the conversion of the Nepafenac prodrug to the active NSAID, amfenac. This reaction is catalyzed by hydrolase enzymes located within various intraocular tissues.9

Secondary Metabolism

Systemically, amfenac undergoes extensive further metabolism to create more polar, water-soluble metabolites that can be easily excreted. The primary metabolic pathway involves hydroxylation of the aromatic ring, followed by conjugation with glucuronic acid to form glucuronide conjugates.3 Radiochromatographic analyses have confirmed that, with the exception of amfenac itself, nearly all metabolites in the plasma are in the form of these glucuronide conjugates.9

Cytochrome P450 (CYP) Involvement

In vitro studies have demonstrated that at concentrations far exceeding those observed clinically, neither Nepafenac nor amfenac significantly inhibits the activity of the major human CYP450 isozymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4).9 This indicates a very low potential for clinically significant drug-drug interactions involving the CYP-mediated metabolism of co-administered systemic medications.

Excretion and Elimination

The final step in the pharmacokinetic journey is the elimination of the metabolites from the body.

Primary Route of Excretion

Studies involving oral administration of radiolabeled (14C) Nepafenac to healthy human volunteers have identified urinary excretion as the major route of elimination. Approximately 85% of the administered radioactive dose was recovered in the urine.9

Secondary Route of Excretion

Fecal excretion accounted for a much smaller portion, representing approximately 6% of the total dose.9

Parent Drug in Urine

Importantly, neither the parent drug Nepafenac nor its active metabolite amfenac were quantifiable in the urine of study subjects.9 This finding confirms that the drug is completely and extensively metabolized to its more polar conjugates before being eliminated by the kidneys.

Clinical Efficacy and Therapeutic Applications

The clinical utility of Nepafenac is well-established through a robust program of clinical trials that have defined its approved indications, optimized its dosing regimens, and demonstrated its value in specific patient populations. The evolution from the original Nevanac® formulation to the more convenient Ilevro® formulation highlights a strategic approach to meeting clinical needs and improving patient adherence.

Approved Indications and Dosing Regimens

Nepafenac has secured regulatory approval in major markets worldwide for key ophthalmic indications.

Approved Indications

• Primary Indication (United States & European Union): Nepafenac is indicated for the prevention and treatment of postoperative pain and inflammation associated with cataract surgery.[1]
• Additional Indication (European Union): In the EU, its indication is expanded to include the reduction in the risk of postoperative macular edema (ME) associated with cataract surgery in patients with diabetes.[1] This specific indication leverages its proven ability to penetrate the posterior segment of the eye.

Dosage and Administration

The dosing regimen varies between the two commercially available formulations:

• Nevanac® (0.1% Suspension): The standard dose is one drop instilled into the conjunctival sac of the affected eye(s) three times daily (TID). Treatment typically begins one day prior to cataract surgery, continues on the day of surgery, and extends for the first two weeks of the postoperative period.[10]
• Ilevro® (0.3% Suspension): The recommended dose is one drop instilled into the affected eye(s) once daily (QD). The treatment schedule is similar, beginning one day before surgery, continuing on the day of surgery, and through the first two weeks postoperatively. The protocol also specifies that an additional drop should be administered 30 to 120 minutes prior to the surgical procedure.[13]
• For Macular Edema Prevention (EU): The TID regimen with the 0.1% suspension is extended for up to 60 days postoperatively in diabetic patients.[10]

Use in Special Populations

• Pediatrics: Nepafenac is approved for use in children aged 10 years and older.[15] For younger pediatric age groups, a waiver for investigation was granted by regulatory authorities, meaning specific studies in this population were not required.[1]
• Hepatic and Renal Impairment: Due to the very low systemic exposure following topical ocular administration, no dose adjustments are considered necessary for patients with underlying hepatic or renal disease.[10]

Analysis of Pivotal Clinical Trial Data

The efficacy of Nepafenac has been validated in numerous large-scale, multicenter, randomized, and controlled clinical trials.

Phase 3 Trials for Initial Approval (Superiority to Vehicle)

The foundational evidence for Nepafenac's efficacy comes from pivotal Phase 3 trials that compared it to a vehicle (placebo) control. These studies consistently demonstrated a statistically significant benefit.

• In a large Phase 3 study supporting the approval of the 0.3% formulation, 68.4% of patients treated with Nepafenac were "cured" (defined as zero aqueous cells and flare) of inflammation by postoperative day 14, compared to only 34.0% of patients in the vehicle group. In the same study, 91.0% of Nepafenac-treated patients were pain-free by day 14, versus 49.7% in the vehicle group.[23]
• Key trials registered on clinicaltrials.gov, such as NCT01426854, NCT00405730, and NCT00333255, provided the core data comparing Nepafenac 0.1% to both vehicle and active comparators like ketorolac, establishing its place in therapy.[30]

Clinical Development of Ilevro® (0.3% QD Formulation)

The clinical program for Ilevro® was not designed to prove superiority over the existing Nevanac® formulation. Instead, it was a strategic effort to demonstrate that a more convenient once-daily dosing regimen could provide efficacy that was non-inferior to the established three-times-daily regimen.13

• Two large Phase 3 trials, C-09-055 and C-11-003, were central to this effort. They compared Nepafenac 0.3% QD to both Nepafenac 0.1% TID (the approved regimen) and vehicle.[31]
• The results of these trials successfully demonstrated that the once-daily 0.3% formulation was effective and safe, showing superiority to vehicle and non-inferiority to the active control arm (Nevanac® 0.1% TID). This provided the regulatory basis for approving a product with a significant advantage in patient convenience and adherence.[31]

Phase 4 (Post-Marketing) Studies

Following its approval, Nepafenac has been evaluated in several Phase 4 studies. These trials have often focused on comparative effectiveness against other active NSAIDs, exploring more nuanced endpoints such as the degree of prostaglandin inhibition (NCT01021761) and the relative aqueous humor penetration (NCT01001806) when compared to agents like ketorolac and bromfenac.32

The clinical journey of Nepafenac illustrates a sophisticated lifecycle management strategy. The initial development focused on establishing fundamental efficacy against placebo. This was followed by a strategic formulation change (Ilevro®) aimed squarely at improving patient convenience to better compete in a crowded market. Finally, the pursuit of the macular edema indication in diabetic patients carved out a specialized niche, leveraging the drug's unique pharmacokinetic properties to address a significant unmet clinical need in a high-risk population.

Table 1: Summary of Key Clinical Trials for Nepafenac Formulations

Trial Identifier	Phase	Formulation(s) Studied	Comparator(s)	Primary Indication	Key Efficacy Endpoints	Summary of Outcome	Source(s)
C-09-055 / C-11-003	3	Nepafenac 0.3% (QD)	Nepafenac 0.1% (TID), Vehicle	Postoperative pain and inflammation after cataract surgery	Percentage of patients with cure (no cells/flare), Percentage of patients pain-free	Nepafenac 0.3% QD was superior to vehicle and non-inferior to Nepafenac 0.1% TID for resolving inflammation and pain.	31
NCT01426854	3	Nepafenac	Placebo	Ocular pain and inflammation after cataract surgery	Resolution of inflammation and pain	Nepafenac was superior to placebo.	30
Phase 3 (Unnamed)	3	Nepafenac 0.3% (QD)	Vehicle	Postoperative pain and inflammation after cataract surgery	Inflammation cure rate (Day 14), Pain-free rate (Day 14)	Cure rate: 68.4% (Nepafenac) vs. 34.0% (Vehicle). Pain-free rate: 91.0% (Nepafenac) vs. 49.7% (Vehicle).	23
NCT00405730	3	Nepafenac 0.1%	Ketorolac 0.5%, Placebo	Postoperative pain and inflammation after cataract surgery	Resolution of inflammation and pain	Comparison of efficacy against an active comparator and placebo.	30
NCT01021761	4	Nepafenac 0.1%	Ketorolac 0.45%, Bromfenac 0.09%	Postoperative inflammation after cataract surgery	Inhibition of Prostaglandin E2 (PGE2​)	Post-marketing study to compare pharmacodynamic effects of different NSAIDs.	33
NCT01001806	4	Nepafenac 0.1%	Ketorolac 0.45%, Bromfenac 0.09%	Postoperative inflammation after cataract surgery	Peak aqueous humor penetration	Post-marketing study to compare pharmacokinetic penetration of different NSAIDs.	33

Safety, Tolerability, and Risk Management

The safety profile of Nepafenac is well-defined and is characterized by a favorable balance of local tolerability and minimal systemic risk. The primary safety concerns are ocular in nature and are consistent with the known effects of the topical NSAID class. A thorough understanding of its adverse event profile, contraindications, and potential drug interactions is essential for its safe and effective use.

Profile of Adverse Events

The adverse events associated with Nepafenac are predominantly localized to the eye.

Common Ocular Effects

The most frequently reported side effects are generally mild and transient. These include:

• A temporary stinging or burning sensation upon instillation, typically lasting for one to two minutes.[16]
• Ocular surface irritation, including eye redness (hyperemia) and a feeling that something is in the eye (foreign body sensation).[15]
• Temporarily blurred or unstable vision immediately following application.[18]
• Headache has also been reported as a common adverse event.[15]

Serious Ocular Effects and Class Warnings

While generally well-tolerated, Nepafenac carries important warnings related to more serious, albeit less common, ocular adverse events. These are class effects for topical NSAIDs.

• Corneal Effects: The most significant risk is potential damage to the cornea. Prolonged use of topical NSAIDs (typically beyond the recommended 14 days for standard post-op care) can increase the risk of keratitis (inflammation of the cornea), corneal epithelial breakdown, corneal thinning, erosion, ulceration, and in rare cases, perforation.[9] These events can be sight-threatening. Patients who show any evidence of corneal epithelial breakdown should immediately discontinue the use of Nepafenac and be monitored closely.[10]
• Delayed Healing: Topical NSAIDs can slow or delay the natural wound healing process of the ocular surface. This is particularly relevant after surgery. The risk of delayed healing may be increased when Nepafenac is used concomitantly with topical corticosteroids.[9]
• Increased Bleeding Tendency: There is a potential for topical NSAIDs to increase bleeding time by interfering with thrombocyte aggregation. Reports exist of increased bleeding of ocular tissues, such as hyphemas (blood in the anterior chamber), in conjunction with ocular surgery. Therefore, caution is warranted when treating patients with known bleeding tendencies or those receiving other medications that may prolong bleeding time.[9]

Systemic Effects

Due to the very low systemic absorption of Nepafenac after topical ocular administration, systemic side effects are rare. Some non-ocular effects such as nausea, vomiting, and runny nose have been reported in post-marketing surveillance.34

Contraindications, Warnings, and Precautions

The use of Nepafenac is contraindicated in certain individuals, and specific precautions must be observed in others.

Contraindications

Nepafenac is strictly contraindicated in:

• Patients with a known hypersensitivity to Nepafenac, any of the excipients in the formulation (e.g., benzalkonium chloride), or to other NSAIDs.[10]
• Patients who have previously experienced attacks of asthma, urticaria (hives), or acute rhinitis that were precipitated by the use of acetylsalicylic acid (aspirin) or other NSAIDs.[10]

Warnings and Precautions

• Cross-Sensitivity: There is a potential for cross-sensitivity between Nepafenac and other NSAIDs, including acetylsalicylic acid and other phenylacetic acid derivatives. Caution should be exercised when treating individuals with a known sensitivity to these drugs.[9]
• High-Risk Patient Populations: Patients with certain underlying conditions are at a higher risk for developing corneal adverse events. These include patients with diabetes mellitus, rheumatoid arthritis, dry eye syndrome, or those who have undergone complicated or repeated ocular surgeries. These individuals should be monitored with extra care.[10]
• Pregnancy and Lactation: The use of prostaglandin-inhibiting drugs during the third trimester of pregnancy is generally avoided due to the risk of premature closure of the fetal ductus arteriosus.[10] Although systemic exposure to Nepafenac is negligible, its use is not recommended during pregnancy, especially late pregnancy, unless the potential benefit justifies the potential risk.[10] It is unknown whether Nepafenac or its metabolites are excreted in human breast milk.[16]
• Contact Lens Wear: The preservative benzalkonium chloride can be absorbed by soft contact lenses and may cause discoloration or irritation. Patients should be instructed to remove their contact lenses before instilling Nepafenac and to wait at least 15 minutes before reinserting them.[10]

Analysis of Drug-Drug Interactions

The potential for drug-drug interactions with Nepafenac must be considered in the context of its pharmacokinetic profile. The long list of theoretical interactions based on its NSAID class is largely mitigated by its minimal systemic absorption.

Topical Interactions

The most clinically relevant interaction is with other topical ophthalmic drugs.

• Topical Corticosteroids: Concomitant use of topical NSAIDs and topical steroids may increase the potential for problems with wound healing. Both drug classes are known to slow or delay healing, and their effects may be additive.[9]

Systemic Interactions

While clinically significant systemic interactions are unlikely, prescribers should be aware of the theoretical risks based on the NSAID class.

• Other NSAIDs: Co-administration with systemic NSAIDs (e.g., ibuprofen, naproxen) could theoretically increase the risk of adverse effects, although this is unlikely given the low systemic dose from the eye drops.[16]
• Anticoagulants and Anti-platelet Agents: Caution is advised when using Nepafenac in patients taking medications that prolong bleeding time, such as warfarin ("blood thinners") or clopidogrel. The potential for topical NSAIDs to increase bleeding of ocular tissues is the primary concern.[10]
• Database-Listed Interactions: Comprehensive drug databases list numerous potential interactions, such as an increased risk of gastrointestinal bleeding when combined with certain antidepressants (e.g., amitriptyline, imipramine) or an increased risk of adverse effects when combined with dozens of other NSAIDs.[3] These are based on the systemic pharmacology of the NSAID class and are of low clinical relevance for a topical ophthalmic product like Nepafenac due to its negligible systemic exposure.

The safety profile of Nepafenac is thus a paradox. It carries a lengthy list of theoretical systemic risks inherited from its drug class, but the pharmacokinetic reality dictates that the actual, clinically meaningful risks are almost exclusively local to the eye. The clinician's primary focus for risk management should therefore be on monitoring ocular health, particularly corneal integrity, and ensuring strict adherence to the recommended duration of therapy to avoid the complications of prolonged use.

Table 2: Clinically Relevant Drug Interactions and Safety Precautions for Nepafenac

Interacting Agent/Class or Condition	Potential Effect	Mechanism & Clinical Relevance	Recommended Action/Precaution	Source(s)
Topical Corticosteroids (e.g., Prednisolone, Dexamethasone)	Increased potential for delayed or impaired wound healing.	Both NSAIDs and corticosteroids can independently slow corneal epithelial healing. The effect may be additive. This is a clinically relevant interaction in the postoperative setting.	Use with caution. Monitor corneal health and wound healing closely if concomitant use is necessary.	9
Systemic Anticoagulants / Anti-platelet Agents (e.g., Warfarin, Clopidogrel)	Potential for increased bleeding of ocular tissues (e.g., hyphema) during and after surgery.	NSAIDs can interfere with thrombocyte aggregation. While systemic effects are minimal, high local drug concentrations could affect bleeding at the surgical site.	Use with caution in patients with known bleeding tendencies or those on these medications. Monitor for signs of ocular bleeding.	10
Other NSAIDs (Topical or Systemic)	Increased risk of ocular surface toxicity and delayed healing.	Additive pharmacological effect on the ocular surface. Increased risk of corneal adverse events associated with the NSAID class.	Avoid concomitant use of different topical NSAIDs. Inform the physician about any systemic NSAID use.	3
Condition: Diabetes Mellitus, Rheumatoid Arthritis, Dry Eye Disease	Increased risk of serious corneal adverse events (keratitis, thinning, perforation).	These conditions may compromise the health of the corneal epithelium, making it more susceptible to the potential toxicity of topical NSAIDs.	Use with caution and monitor these patients closely for any signs of corneal epithelial breakdown. Consider alternative therapies if significant surface disease is present.	10
Condition: Pregnancy (Late Stage)	Risk of premature closure of the fetal ductus arteriosus.	Prostaglandin inhibitors are known to have effects on the fetal cardiovascular system. This is a well-established NSAID class effect.	Avoid use during the third trimester of pregnancy unless the potential benefit outweighs the risk.	10
Contact Lens Wear	Absorption of benzalkonium chloride preservative by soft lenses, leading to irritation.	The preservative can accumulate in the lens material and be released over time, causing ocular irritation.	Instruct patients to remove soft contact lenses prior to instillation and wait at least 15 minutes before reinsertion.	10

Comparative Analysis with Other Ophthalmic NSAIDs

The clinical positioning of Nepafenac is best understood through a comparative analysis with other leading topical NSAIDs, namely ketorolac, diclofenac, and bromfenac. This comparison reveals that Nepafenac's value proposition is not based on superior anti-inflammatory potency alone, but rather on a uniquely optimized balance of efficacy, ocular surface safety, and dosing convenience that stems directly from its prodrug design.

Nepafenac vs. Ketorolac

Ketorolac is one of the most established and widely studied ophthalmic NSAIDs, making it a critical benchmark for comparison.

• Efficacy: Multiple head-to-head studies and a comprehensive meta-analysis have concluded that Nepafenac and ketorolac are equally effective in the management of postoperative cataract surgery outcomes. There is no statistically significant difference between the two drugs in their ability to control anterior chamber inflammation (cells and flare), reduce the incidence of postoperative macular edema, improve visual acuity, or maintain mydriasis during surgery.[24]
• Tolerability and Safety: This is the key area of differentiation. The same meta-analysis that found equal efficacy also concluded that Nepafenac is statistically superior to ketorolac in terms of patient tolerability. Patients treated with Nepafenac experienced a significantly lower incidence of common side effects such as postoperative conjunctival hyperemia and ocular discomfort (stinging, burning).[35] This superior tolerability is attributed to Nepafenac's prodrug nature, which minimizes the exposure of the ocular surface to the active, and potentially more irritating, NSAID molecule.
• Dosing Convenience: Standard dosing for ketorolac 0.5% (Acular®) is four times daily (QID).[36] This is less convenient for patients than the three-times-daily (TID) regimen of Nepafenac 0.1% (Nevanac®) and significantly less convenient than the once-daily (QD) regimen of Nepafenac 0.3% (Ilevro®).[15]

Nepafenac vs. Diclofenac

Diclofenac is another veteran ophthalmic NSAID, and comparisons have largely focused on ocular surface safety.

• Ocular Surface Safety: A randomized, controlled clinical trial directly comparing Nepafenac 0.1% to diclofenac 0.1% after cataract surgery found that Nepafenac has a superior ocular surface safety profile. At four weeks postoperatively, the diclofenac group had significantly higher conjunctival and corneal fluorescein staining scores, an objective measure of epithelial cell damage.[37] This finding provides strong clinical evidence to support the theoretical safety benefit of the prodrug mechanism; by remaining inert during corneal transit, Nepafenac causes less disruption to the corneal epithelium than diclofenac, which is administered in its active form.
• Analgesic Effect: In the specific context of providing analgesia for pain during intravitreal injections, one study found no statistically significant difference in pain scores among Nepafenac, ketorolac, diclofenac, and a placebo group. However, the study did note a trend towards lower pain scores in the Nepafenac group, though this did not reach statistical significance.[38]

Positioning Against Bromfenac and Other Agents

Bromfenac has emerged as a strong competitor, primarily due to its convenient dosing schedule.

• Dosing Convenience: Bromfenac is available in formulations that allow for twice-daily (BID) or once-daily (QD) dosing, which is a major advantage for patient compliance.[39] The development of the once-daily Ilevro® was a direct strategic response to competition from convenient agents like bromfenac.
• Efficacy: Studies have generally shown bromfenac to have comparable efficacy to ketorolac and diclofenac in treating postoperative inflammation and pain.[40] Head-to-head trials directly comparing Nepafenac 0.3% QD to bromfenac QD are less common but represent an important area for future research.
• Comparison to Steroids: When compared to the "gold standard" anti-inflammatory, prednisolone (a corticosteroid), studies show that prednisolone is more effective at reducing objective signs of inflammation (anterior chamber cells and flare). However, the NSAID class, including Nepafenac, was found to be better at controlling subjective symptoms of pain and hyperemia, particularly in the early postoperative period.[24] This suggests a complementary role, and many clinicians use a combination of a steroid and an NSAID postoperatively.

In summary, the competitive landscape shows that while the top-tier ophthalmic NSAIDs have largely equivalent anti-inflammatory efficacy, Nepafenac carves out its clinical niche through superior ocular surface tolerability and flexible, convenient dosing options. A clinician might choose Nepafenac over ketorolac or diclofenac for a patient with a sensitive ocular surface, pre-existing dry eye, or a history of intolerance to other topical drops. The choice between the TID Nevanac® and the QD Ilevro® allows the clinician to tailor the therapy to the patient's likely adherence.

Table 3: Comparative Profile of Leading Ophthalmic NSAIDs

Attribute	Nepafenac (Nevanac®/Ilevro®)	Ketorolac (Acular®/Acuvail®)	Diclofenac (Voltaren®)	Bromfenac (Prolensa®/Xibrom®)
Primary Mechanism	Prodrug; converted to amfenac; inhibits COX-1 & COX-2.	Active drug; inhibits COX-1 & COX-2.	Active drug; inhibits COX-1 & COX-2.	Active drug; potent inhibitor of COX-2, also inhibits COX-1.
Standard Dosing Frequency	0.1% TID; 0.3% QD.	0.5% QID; 0.45% BID.	0.1% QID.	0.09% BID; 0.07% QD.
Efficacy vs. Inflammation	Equivalent to ketorolac.	Equivalent to nepafenac and diclofenac.	Equivalent to ketorolac.	Comparable to other NSAIDs.
Efficacy vs. Pain	Equivalent to ketorolac.	Equivalent to nepafenac and diclofenac.	Equivalent to other NSAIDs.	Comparable to other NSAIDs.
Ocular Surface Tolerability	Superior to ketorolac and diclofenac (less stinging, less epithelial damage).	Inferior to nepafenac (more stinging and hyperemia reported).	Inferior to nepafenac (more corneal staining/epithelial damage reported).	Generally well-tolerated; comparative data vs. nepafenac is limited.
CME Prevention/Treatment	Indicated for risk reduction in diabetics (EU). Equivalent to ketorolac for treatment.	Effective for treatment of pseudophakic CME.	Effective for treatment of pseudophakic CME.	Effective for treatment of pseudophakic CME.
Key Differentiator	Prodrug design leading to excellent balance of efficacy, safety, and convenience.	Longest track record and extensive clinical data.	Generic availability and long history of use.	High potency and convenient QD/BID dosing.
Source(s)	35	35	37	36

Regulatory and Commercial Landscape

The trajectory of Nepafenac from development to a globally recognized ophthalmic therapy is a textbook example of modern pharmaceutical strategy, characterized by targeted regulatory approvals, robust intellectual property protection, and savvy product lifecycle management.

Global Regulatory Approval History

Nepafenac has successfully navigated the rigorous approval processes of major regulatory agencies worldwide.

• United States Food and Drug Administration (FDA):
• Nevanac® (0.1% Suspension): The initial formulation received its first FDA approval on August 19, 2005, under New Drug Application (NDA) 21-862. The approved indication was for the treatment of pain and inflammation associated with cataract surgery.[29]
• Ilevro® (0.3% Suspension): The higher-concentration, once-daily formulation was approved under NDA 203-491. The review was completed in late 2012, with the product being approved for the same indication as Nevanac® but offering a more convenient dosing schedule.[13] This was a significant step in the product's lifecycle, requiring a full NDA with new clinical trial data.
• European Medicines Agency (EMA):
• Nepafenac is authorized for use in the European Union.[1] In addition to the standard indication for postoperative pain and inflammation, Nevanac® uniquely holds an EMA approval for the reduction in the risk of postoperative macular edema (ME) associated with cataract surgery in diabetic patients.[1] This specialized indication distinguishes it from many competitors in the European market.
• Global Reach:
• Beyond the US and EU, Alcon successfully registered Nepafenac-containing products for ocular use in a total of 84 countries worldwide, establishing it as a global standard in ophthalmic care.[43]

Key Stakeholders and Market Positioning

The development and commercialization of Nepafenac have been driven by a major player in the ophthalmic pharmaceutical space.

• Original Applicant and Sponsor: Alcon, Inc., based in Fort Worth, Texas, was the original developer and sponsor of both the Nevanac® and Ilevro® NDAs.[17] Alcon's expertise in ophthalmology was instrumental in the drug's successful development and launch.
• Corporate Ownership and Marketing: Alcon was subsequently acquired by Novartis AG, and as a result, the patents and global marketing rights became associated with Novartis.[2] More recently, marketing rights for the brand in the US have been transferred to Harrow Eye.[44]
• API Manufacturers: While the brand is controlled by a single entity, the active pharmaceutical ingredient (API) for Nepafenac is produced by a diverse range of certified manufacturers across the globe, including facilities in China, India, the United States, and the Czech Republic, ensuring a stable global supply chain.[45]

Intellectual Property and Product Lifecycle

A strong patent portfolio and strategic product evolution have been key to maximizing the commercial lifespan of Nepafenac.

• Patent Protection: Nepafenac is protected by multiple U.S. patents covering its topical suspension compositions. These patents, primarily assigned to Alcon/Novartis, are crucial for defending its market position. For example, U.S. Patent 7,834,059 (issued in 2010) and U.S. Patent 8,071,648 (issued in 2011) provide protection for the drug product and its method of use, with expiration dates extending into the mid-to-late 2020s.[2]
• Generic Availability: Due to this robust and ongoing patent protection, there is currently no generic version of Nevanac® or Ilevro® available in the United States.[15] This market exclusivity is a direct result of the successful intellectual property strategy.
• Lifecycle Management: The commercial history of Nepafenac is a clear demonstration of effective product lifecycle management. The initial market entry was secured with Nevanac® 0.1% TID. Faced with competitive pressure from other NSAIDs offering more convenient dosing, the company did not cede the market. Instead, it invested in developing Ilevro® 0.3% QD. This new formulation, supported by new clinical trials and a separate NDA, offered a significant improvement in patient convenience, thereby refreshing the product line, defending against competitors, and extending the franchise's commercial viability.[13] This strategic move from a TID to a QD formulation, combined with the pursuit of a niche indication (ME in diabetics) in Europe, shows a sophisticated, science-driven approach to maximizing the clinical and commercial value of a single molecule over its entire patent life.

Synthesis and Expert Recommendations

The comprehensive analysis of Nepafenac reveals a molecule whose clinical success and therapeutic value are fundamentally rooted in its intelligent design as a prodrug. This core chemical feature is not merely a formulation gimmick but the central driver of its advantageous pharmacokinetic profile, its differentiated safety and tolerability, and its expanded clinical utility. It represents a benchmark in ophthalmic drug development, where molecular engineering and pharmaceutical science have been harmonized to solve key clinical challenges.

The central thesis of this report is that the prodrug mechanism is the unifying principle explaining Nepafenac's clinical performance. This design choice directly leads to a cascade of favorable properties. Its high lipophilicity ensures rapid transit across the corneal barrier, while its inertness during this phase protects the delicate ocular surface. The subsequent targeted bioactivation by intraocular hydrolases concentrates the potent anti-inflammatory activity of its metabolite, amfenac, precisely in the tissues where it is most needed—the iris, ciliary body, and retina. This elegant mechanism simultaneously explains its superior ocular surface tolerability when compared to NSAIDs like ketorolac and diclofenac, and its proven ability to reach the posterior segment to a degree sufficient for the prevention of macular edema. The resulting pharmacokinetic profile—high local concentration in the eye with negligible systemic exposure—provides a wide therapeutic window, allowing for potent local efficacy with minimal risk of systemic NSAID-class side effects.

In the competitive landscape of ophthalmic NSAIDs, Nepafenac is not positioned as being superior in raw anti-inflammatory potency; clinical data consistently show its efficacy to be on par with other leading agents like ketorolac. Its true clinical value lies in its optimized overall profile. It offers a compelling balance of proven efficacy, superior ocular surface safety, and convenient dosing options (particularly with the once-daily Ilevro® formulation). This makes Nepafenac a first-line therapeutic choice for many clinicians, especially in the context of modern premium cataract surgery where minimizing patient discomfort and ensuring excellent visual outcomes are paramount. It is an especially strong candidate for patients with pre-existing ocular surface disease, those with diabetes who are at higher risk for macular edema, or any patient for whom adherence to a simpler dosing regimen is a critical factor for success.

Based on this analysis, the following recommendations for future research and development are proposed:

1. Direct Comparative Effectiveness Trials: While extensive data exists comparing Nepafenac 0.1% to competitors, there is a need for large, well-controlled, head-to-head clinical trials comparing the once-daily Nepafenac 0.3% (Ilevro®) formulation directly against other once-daily ophthalmic NSAIDs, such as bromfenac 0.07%. Such studies would provide clinicians with definitive data on the relative efficacy and tolerability of the most convenient treatment options.
2. Expansion into Posterior Segment Indications: Given its proven ability to penetrate the posterior segment and its EU indication for diabetic macular edema prophylaxis, further investigation into its efficacy for other posterior segment inflammatory conditions is warranted. This could include studies on its role in managing inflammation associated with intravitreal injections, non-infectious uveitis, or other forms of macular edema.
3. Development of Preservative-Free Formulations: A significant opportunity exists to further enhance Nepafenac's safety profile by developing a preservative-free formulation. The current formulations contain benzalkonium chloride, a preservative known to cause ocular surface toxicity in some patients, particularly those with severe dry eye disease or those requiring long-term treatment. A preservative-free version would solidify its position as the safest-in-class option for sensitive eyes.
4. Exploration of Novel Sustained-Release Delivery Systems: The future of ophthalmic drug delivery lies in reducing the burden of patient self-administration. Research into novel sustained-release platforms for Nepafenac, such as the biodegradable hydrogel intracanalicular inserts currently under investigation [46], should be prioritized. A successful sustained-release product could provide consistent drug delivery over weeks or months from a single in-office administration, effectively eliminating issues of patient non-adherence and representing the next major evolution in postoperative inflammatory control.

Works cited

1. Nepafenac | C15H14N2O2 | CID 151075 - PubChem, accessed August 5, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Nepafenac
2. Nepafenac - Wikipedia, accessed August 5, 2025, https://en.wikipedia.org/wiki/Nepafenac
3. Nepafenac: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 5, 2025, https://go.drugbank.com/drugs/DB06802
4. CAS 78281-72-8: Nepafenac | CymitQuimica, accessed August 5, 2025, https://cymitquimica.com/cas/78281-72-8/
5. Nepafenac CAS:78281-72-8 - Ruixibiotech, accessed August 5, 2025, https://www.ruixibiotech.com/pts/nepafenac
6. Nepafenac (AHR 9434, AL 6515, CAS Number: 78281-72-8) | Cayman Chemical, accessed August 5, 2025, https://www.caymanchem.com/product/23700/nepafenac
7. nepafenac - PharmGKB, accessed August 5, 2025, https://www.pharmgkb.org/chemical/PA165958407
8. CHEBI:75922 - nepafenac - EMBL-EBI, accessed August 5, 2025, https://www.ebi.ac.uk/chebi/chebiOntology.do?chebiId=CHEBI:75922
9. Mechanism of Action: Nepafenac, accessed August 5, 2025, https://www.centaurpharma.com/downloads/Nepacent2018.pdf
10. NEVANAC® - Novartis, accessed August 5, 2025, https://www.novartis.com/sg-en/sites/novartis_sg/files/Nevanac-Nov2020.SIN-App220621.pdf
11. Nepafenac - CAS RN: 78281-72-8 - TCI Chemicals, accessed August 5, 2025, https://www.tcichemicals.com/US/en/p/N0932
12. Nevanac, INN-amfenac amide - EMA, accessed August 5, 2025, https://www.ema.europa.eu/en/documents/scientific-discussion/nevanac-epar-scientific-discussion_en.pdf
13. 203491Orig1s000 - accessdata.fda.gov, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ClinPharmR.pdf
14. nepafenac | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 5, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7564
15. Nevanac (nepafenac): Uses, Side Effects, Dosage & Reviews - GoodRx, accessed August 5, 2025, https://www.goodrx.com/nevanac/what-is
16. nepafenac 0.3 % eye drops,suspension - Kaiser Permanente, accessed August 5, 2025, https://healthy.kaiserpermanente.org/health-wellness/drug-encyclopedia/drug.nepafenac-0-3-eye-drops-suspension.576342
17. Chemistry Review(s) - accessdata.fda.gov, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021862s000_Nevanac_chemr.pdf
18. Nepafenac (ophthalmic route) - Side effects & dosage - Mayo Clinic, accessed August 5, 2025, https://www.mayoclinic.org/drugs-supplements/nepafenac-ophthalmic-route/description/drg-20067489
19. Nevanac, Ilevro (nepafenac ophthalmic) dosing, indications ..., accessed August 5, 2025, https://reference.medscape.com/drug/nevanac-ilevro-nepafenac-ophthalmic-343662
20. 203491Orig1s000 - accessdata.fda.gov, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000OtherR.pdf
21. What is the mechanism of Nepafenac? - Patsnap Synapse, accessed August 5, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-nepafenac
22. go.drugbank.com, accessed August 5, 2025, https://go.drugbank.com/drugs/DB06802#:~:text=Nepafenac%20is%20a%20prodrug.,the%20COX1%20and%20COX2%20activity.&text=Nepafenac%20rapidly%20cross%20the%20cornea,faster%20than%20diclofenac%20in%20vitro).&text=Amfenac%20has%20high%20affinity%20toward%20serum%20albumin%20proteins..%26text%3DAmfenac%2520has%2520high%2520affinity%2520toward%2520serum%2520albumin%2520proteins.&sa=D&source=editors&ust=1754389654709784&usg=AOvVaw1DOHJB9UN0xAuqSmh7CM8K)
23. Nepafenac - PMC, accessed August 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5768593/
24. A comparative study of various topical nonsteroidal anti-inflammatory drugs to steroid drops for control of post cataract surgery inflammation - PMC, accessed August 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5084497/
25. www.caymanchem.com, accessed August 5, 2025, https://www.caymanchem.com/product/23700/nepafenac#:~:text=Nepafenac%20is%20a%20prodrug%20form,%2D1%20and%20COX%2D2.&text=Nepafenac%20is%20an%20inhibitor%20of,isolated%20rabbit%20iris%2Fciliary%20body.
26. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye - PubMed, accessed August 5, 2025, https://pubmed.ncbi.nlm.nih.gov/26474497/
27. Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond - PubMed, accessed August 5, 2025, https://pubmed.ncbi.nlm.nih.gov/12769666/
28. annex i summary of product characteristics - Nevanac INN-Nepafenac, accessed August 5, 2025, https://ec.europa.eu/health/documents/community-register/2012/20120924124177/anx_124177_en.pdf
29. Nevanac (nepafenac) FDA Approval History - Drugs.com, accessed August 5, 2025, https://www.drugs.com/history/nevanac.html
30. Nepafenac Completed Phase 3 Trials for Cataracts Treatment | DrugBank Online, accessed August 5, 2025, https://go.drugbank.com/drugs/DB06802/clinical_trials?conditions=DBCOND0028228&phase=3&purpose=treatment&status=completed
31. 203491Orig1s000 - accessdata.fda.gov, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000SumR.pdf
32. Nepafenac Unknown Status Phase 4 Trials for Cataracts Treatment | DrugBank Online, accessed August 5, 2025, https://go.drugbank.com/drugs/DB06802/clinical_trials?conditions=DBCOND0028228&phase=4&purpose=treatment&status=unknown_status
33. Nepafenac Completed Phase 4 Trials for Cataracts Treatment | DrugBank Online, accessed August 5, 2025, https://go.drugbank.com/drugs/DB06802/clinical_trials?conditions=DBCOND0028228&phase=4&purpose=treatment&status=completed
34. Nepafenac Ophthalmic: MedlinePlus Drug Information, accessed August 5, 2025, https://medlineplus.gov/druginfo/meds/a606007.html
35. Comparison of the efficacy and patients' tolerability of Nepafenac ..., accessed August 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5333896/
36. (PDF) A comparative study of various topical nonsteroidal anti-inflammatory drugs to steroid drops for control of post cataract surgery inflammation - ResearchGate, accessed August 5, 2025, https://www.researchgate.net/publication/309168794_A_comparative_study_of_various_topical_nonsteroidal_anti-inflammatory_drugs_to_steroid_drops_for_control_of_post_cataract_surgery_inflammation
37. Comparison of effect of nepafenac and diclofenac ophthalmic ..., accessed August 5, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4786065/
38. Comparison of the Analgesic Effect of Nepafenac 0.1%, Ketorolac 0.5%, and Diclofenac 0.1% Ophthalmic Solution during Intravitreal Injection - Journal of the Medical Association of Thailand, accessed August 5, 2025, http://www.jmatonline.com/PDF/982-988-PB-12592.pdf
39. Therapeutic Class Overview Ophthalmic Nonsteroidal Anti-Inflammatory Drugs - Medicaid.nv.gov, accessed August 5, 2025, https://www.medicaid.nv.gov/Downloads/provider/Ophthalmic%20Nonsteroidal%20Anti_09222016.pdf
40. Comparing NSAIDs - Retinal Physician, accessed August 5, 2025, https://www.retinalphysician.com/issues/2006/september/comparing-nsaids/
41. Drug Approval Package: Nevanac (Nepafenac) NDA #021862, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021862s000_NevanacTOC.cfm
42. Drug Approval Package: Nepafenac NDA #203491 - accessdata.fda.gov, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491_nepafenac_toc.cfm
43. 203491Orig1s000 | FDA, accessed August 5, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000ODMemo.pdf
44. Generic Nevanac Availability - Drugs.com, accessed August 5, 2025, https://www.drugs.com/availability/generic-nevanac.html
45. CoA certified Nepafenac API Manufacturers & Suppliers - Pharmaoffer.com, accessed August 5, 2025, https://pharmaoffer.com/api-excipient-supplier/nsaids/nepafenac/coa
46. Pharmacokinetics of a Hydrogel-based Nepafenac Intracanalicular Insert in Canines - Investors | Ocular Therapeutix, Inc., accessed August 5, 2025, https://investors.ocutx.com/static-files/9886568f-096e-43f3-b2d9-b31322d2ca98
47. Pharmacokinetics of a Hydrogel-based Nepafenac Intracanalicular Insert in Canines | IOVS, accessed August 5, 2025, https://iovs.arvojournals.org/article.aspx?articleid=2783054